RCT: Rivaroxaban for thromboprophylaxis in acutely ill medical patients (MAGELLAN)

Source: N Engl J Med Area: News RCTs of hospitalised patients at increased risk for venous thromboembolism (VTE) have shown the benefits of administering anticoagulant agents for up to 14 days. There is some evidence that the risk of VTE in acutely ill medical patients persists after hospital discharge, but no studies have supported the routine use of extended thromboprophylaxis.   Rivaroxaban is an oral, direct factor Xa inhibitor that is used for the prevention of VTE after elective hip-replacement or knee-replacement surgery in adults. The 'Multicenter, Randomised, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin' (MAGELLAN) assessed the efficacy and safety of rivaroxaban administered for 35 days, vs. enoxaparin administered for 10 days and followed by placebo, in patients ?aged 40 years with reduced mobility and an acute medical illness requiring hospitalisation.   The ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news